05 MAR 2019 | DARMSTADT, GERMANY Merck KGaA, Darmstadt, Germany, a leading science and technology company, today issued an open letter to the shareholders of Versum Materials, Inc. (“Versum”). On March 1, the Versum Board of Directors without any further explanation rejected Merck KGaA, Darmstadt, Germany’s superior proposal to acquire all of the outstanding common stock of... Read more
04 MAR 2019 | BURLINGTON, MASSACHUSETTS, UNITED STATES OF AMERICA Patent covers paired Cas9 nickase technology to advance gene therapy and research, reduce off-target effects Marks MilliporeSigma’s 13th CRISPR patent overall Actively licensing CRISPR-related patents to interested parties Burlington, Massachusetts, March 4, 2019 – MilliporeSigma, a leader in genome editing, today announced that the Canadian Patent Office has allowed... Read more
27 FEB 2019 | DARMSTADT, GERMANY $48 Per Share Proposal Represents a Premium to Current Value of Entegris’ All-stock Proposal Merck KGaA, Darmstadt, Germany, a leading science and technology company, today delivered a letter to the Board of Directors of Versum Materials, Inc. (“Versum”), outlining the terms of a superior proposal to acquire Versum for $48 per share... Read more
19 FEB 2019 | DARMSTADT, GERMANY Proxy-CRISPR technology provides solution to improve genome editing and advance new possibilities for research Helps modify difficult-to-access regions of the genome, increasing genome coverage Merck KGaA, Darmstadt, Germany, a leading science and technology company and leader in genome editing, today announced that the United States Patent and Trademark Office has issued... Read more
BILLERICA, Mass., February 6, 2019 — Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Billerica, Massachusetts. The new building will span 145,000 square feet, offering new laboratory... Read more
Darmstadt, Germany, January 28, 2019 – At the Partners’ Meeting of E. Merck KG, Darmstadt, Germany (EM), last weekend the Merck family partners elected their representatives to the Family Board and Board of Partners in a regularly scheduled election held every five years. The incumbent chairmen of these two boards were re-elected: Dr. Frank Stangenberg-Haverkamp (70), Chairman... Read more
From January 2019, startups from nine different countries will collaborate with Merck KGaA, Darmstadt Germany Selected teams will have the opportunity to extend their stay in the company’s China Innovation Hub in Shanghai For the first time, the program includes a startup specializing in the fight against multi-drug resistant bacteria Darmstadt, Germany, January 16, 2019... Read more
10 DEC 2018 | DARMSTADT, GERMANY genOway to acquire exclusive rights to Merck’s foundational genome-editing patents to produce, sell rodent models New technologies and solutions to be developed using CRISPR/Cas9 to accelerate delivery of better drugs to patients Merck KGaA, Darmstadt, Germany, a leading science and technology company and leader in genome editing, announced that its life... Read more
01 DEC 2018 | DARMSTADT, GERMANY Closing of sale to Procter & Gamble at a cash purchase price of € 3.4 billion completed Successful completion allows Merck KGaA, Darmstadt, Germany, to further focus on innovation driven businesses in Healthcare, Life Science and Performance Materials Transaction successfully closed within an ambitious timeframe Merck KGaA, Darmstadt, Germany, a leading science and... Read more
27 NOV 2018 | DARMSTADT, GERMANY MilliporeSigma’s proxy-CRISPR wins Special Recognition Market Disruptor — Products award Burlington, Massachusetts, November 27, 2018 – MilliporeSigma today announced that it has won two R&D 100 Awards. The 56th annual R&D 100 Awards program, honoring the 100 most innovative and significant technologies introduced in the past year, recognized MilliporeSigma for its BioReliance® Viral and Gene Therapy Assay... Read more